

KRT18 Antibody (monoclonal) (M01)

Mouse monoclonal antibody raised against a full length recombinant KRT18.

Catalog # AT2655a

Product Information

Application	WB, IHC, IF, IP, E
Primary Accession	P05783
Other Accession	BC000180
Reactivity	Human
Host	Mouse
Clonality	monoclonal
Isotype	IgG2a Kappa
Clone Names	2F8
Calculated MW	48058

Additional Information

Gene ID	3875
Other Names	Keratin, type I cytoskeletal 18, Cell proliferation-inducing gene 46 protein, Cytokeratin-18, CK-18, Keratin-18, K18, KRT18, CYK18
Target/Specificity	KRT18 (AAH00180, 1 a.a. ~ 430 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Dilution	WB~~1:500~1000 IHC~~1:100~500 IF~~1:50~200 IP~~N/A E~~N/A
Format	Clear, colorless solution in phosphate buffered saline, pH 7.2 .
Storage	Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
Precautions	KRT18 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.

Background


KRT18 encodes the type I intermediate filament chain keratin 18. Keratin 18, together with its filament partner keratin 8, are perhaps the most commonly found members of the intermediate filament gene family. They are expressed in single layer epithelial tissues of the body. Mutations in this gene have been linked to cryptogenic cirrhosis. Two transcript variants encoding the same protein have been found for this gene.

References


Ectopic coexpression of keratin 8 and 18 promotes invasion of transformed keratinocytes and is induced in

patients with cutaneous squamous cell carcinoma. Yamashiro Y, et al. Biochem Biophys Res Commun, 2010 Aug 27. PMID 20659422. Maternal genes and facial clefts in offspring: a comprehensive search for genetic associations in two population-based cleft studies from Scandinavia. Jugessur A, et al. PLoS One, 2010 Jul 9. PMID 20634891. Keratin variants predispose to acute liver failure and adverse outcome: race and ethnic associations. Strnad P, et al. Gastroenterology, 2010 Sep. PMID 20538000. Significant high expression of cytokeratins 7, 8, 18, 19 in pulmonary large cell neuroendocrine carcinomas, compared to small cell lung carcinomas. Nagashio R, et al. Pathol Int, 2010 Feb. PMID 20398190. Relationship between serum concentrations of keratin-18 and apoptosis in chronic hepatitis C. Gonzalez-Quintela A, et al. Clin Chem Lab Med, 2010 Jun. PMID 20374042.


Images



Antibody Reactive Against Recombinant Protein. Western Blot detection against Immunogen (47.41 KDa) .





KRT18 monoclonal antibody (M01), clone 2F8 Western Blot analysis of KRT18 expression in HeLa ((Cat # AT2655a)




Western Blot analysis of KRT18 expression in transfected 293T cell line by KRT18 monoclonal antibody (M01), clone 2F8.

Lane 1: KRT18 transfected lysate(48.1 KDa).
Lane 2: Non-transfected lysate.


Immunoperoxidase of monoclonal antibody to KRT18 on formalin-fixed paraffin-embedded human liver tissue. [antibody concentration 3 ug/ml]



Immunofluorescence of monoclonal antibody to KRT18 on HeLa cell. [antibody concentration 10 ug/ml]



Immunoprecipitation of KRT18 transfected lysate using anti-KRT18 monoclonal antibody and Protein A Magnetic Bead ([U0007](#)), and immunoblotted with KRT18 MaxPab rabbit polyclonal antibody.



Detection limit for recombinant GST tagged KRT18 is approximately 0.1ng/ml as a capture antibody.

Citations

- [brca2-mutant zebrafish exhibit context- and tissue-dependent alterations in cell phenotypes and response to injury](#)
- [Collagen COL22A1 maintains vascular stability and mutations in are potentially associated with intracranial aneurysms.](#)
- [Intermediate filaments of zebrafish retinal and optic nerve astrocytes and Mller glia: differential distribution of cytokeratin and GFAP.](#)
- [Keratin 18 attenuates estrogen receptor alpha-mediated signaling by sequestering LRP16 in cytoplasm.](#)

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.